SENS

Senseonics Holdings, Inc.

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Senseonics Holdings, Inc. (SENS) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) B+ (3.6) B- (2.9) A- (4.0) A+ (5.0) B+ (3.7)
2026-11-07 B- (3.0) B+ (3.6) B- (3.0) A- (4.1) C+ (2.7) B (3.3)
2026-10-31 B- (3.0) B+ (3.6) B- (3.0) A+ (4.5) C+ (2.7) B (3.3)
2026-10-24 B- (3.0) B+ (3.5) B- (3.0) A (4.3) C+ (2.6) B (3.3)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe